Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Taylor & Francis Group
2020-11-01
|
| 叢編: | Human Vaccines & Immunotherapeutics |
| 主題: | |
| 在線閱讀: | http://dx.doi.org/10.1080/21645515.2020.1741312 |